Topics
Glioblastoma | Treatment | Theranostics
Home > Publications > Topics > Glioblastoma > Treatment > Theranostics
Biau J, Durando X, Boux F, Molnar I, Moreau J, Leyrat B, Guillemin
F, Lavielle A, Cremillieux Y, Seddik K, Dufort S, De Beaumont O,
Thivat E, Le Duc G.
NANO-GBM trial of
AGuIX nanoparticles with radiotherapy and temozolomide in the
treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and
MRI-based biodistribution.
Clin
Transl Radiat Oncol. 2024 Jul 31;48:100833. doi:
10.1016/j.ctro.2024.100833. PMID:
39184998. Interventional study. ˍ
Kumar A, Shukla R.
Current strategic
arsenal and advances in nose to brain nanotheranostics for
therapeutic intervention of glioblastoma multiforme.
J
Biomater Sci Polym Ed. 2024 Sep 9:1-35. doi:
10.1080/09205063.2024.2396721. PMID:
39250527. Review˰ ˍ
*Sangubotla R, Gubbiyappa KS, Devarapogu R, Kim J.
Modern
insights of nanotheranostics in the glioblastoma: An updated
review.
Biochim
Biophys Acta Mol Basis Dis. 2025 Jan 3:167653. doi:
10.1016/j.bbadis.2024.167653. PMID:
39756713. Review˰ ˍ
Ghaedian T, Alipour A, Rakhsha A, Nasrollahi H, Ghaedian M,
Andalibi S, Saffarian A.
Excellent
Response of Glioblastoma Multiforme to [ 177 Lu] Lu-PSMA Therapy.
Clin
Nucl Med. 2025 Apr 28. doi:
10.1097/RLU.0000000000005904. PMID:
40279656. Case report˰
ˍ
Mittra ES, Solnes LB, van der Veldt AAM, Wong J, Aloj L, Heinrich
MC, Chen CT, Rowe SP, Brabander T, Pacey S, Aimone P, Pathak D,
Blumenstein L, Liu Y, Iagaru A.
Phase
1 Study of [177Lu]Lu-NeoB
in Patients with Advanced Solid Tumors Overexpressing
Gastrin-Releasing Peptide Receptor: Preliminary Safety and
Dosimetry Results.
J
Nucl Med. 2025 Dec 4:jnumed.125.270411. doi:
10.2967/jnumed.125.270411. PMID:
41344852. Interventional study. ˍ
López-Rueda A, Pons A, Majos C, Chirife O, Cos M.
Eligibility assessment for yttrium-90
radioembolisation in patients with recurrent glioblastoma: A
single-centre cohort study based on the FRONTIER clinical trial
criteria (NCT05303467).
Radiologia
(Engl Ed). 2026 Mar 2;68(2):501691. doi:
10.1016/j.rxeng.2026.501691. PMID:
41819978˰ ˍ